Publish in this journal
Journal Information
Vol. 110. Num. 1.January - February 2019
Pages e1-e6Pages 1-86
Share
Share
Download PDF
More article options
ePub
Visits
2
Vol. 110. Num. 1.January - February 2019
Pages e1-e6Pages 1-86
Brief Comunication
DOI: 10.1016/j.adengl.2018.11.013
Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings
Reacción granulomatosa en paciente con melanoma metastásico tratado con ipilimumab: primer caso descrito presentando clínica cutánea únicamente
Visits
2
J. Cervantesa,
Corresponding author
J.Cervantes1@umiami.edu

Corresponding author.
, A. Rosena, L. Dehesab, G. Dickinsonc, J. Alonso-Llamazaresa
a Departamento de Dermatología y Cirugía Cutánea, Facultad de Medicina, Universidad Miller de Miami, Miami, Florida, Estados Unidos
b Centro Médico San Francisco, Universidad de California, San Francisco, California, Estados Unidos
c Departamento de Enfermedades Infecciosas, Facultad de Medicina, Universidad Miller de Miami, Miami, Florida, Estados Unidos
This item has received
2
Visits
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (1)
Table 1. Clinical Cases of Sarcoidosis-Like Granulomatous Reaction in Patients Diagnosed with Melanoma or Other Neoplastic Processes Treated With Ipilimumab.
Abstract

Granulomatous sarcoidosis-like reactions affecting multiple organ systems at one time have infrequently been described within weeks to months after initiation of Ipilimumab. We present the first case of a 67-year-old man with isolated cutaneous granulomatous reaction involving the trunk, extremities, and face after eighteen months of treatment with ipilimumab for metastatic melanoma. This case documents the eruption of isolated cutaneous granulomatous reaction as a late treatment-related adverse effect of ipilimumab, highlighting the importance of adequate, prolonged follow-up.

Keywords:
Anti-CTLA4
Immunotherapy
Metastatic melanoma
Sarcoidosis
Granulomatous reaction
Immune-related adverse event
Adverse drug reaction
Resumen

Las reacciones granulomatosas «sarcoidosis-like» secundarias a ipilimumab afectarán simultáneamente a múltiples órganos y característicamente se presentarán semanas o meses después de haber iniciado el tratamiento. Paciente varón de 67 años, quien consulta por reacción cutánea granulomatosa a nivel de tronco, extremidades y rostro. Esta se presentó 18 meses después de haber iniciado tratamiento con ipilimumab, medicamento pautado por el diagnóstico de un melanoma metastásico. Reportamos reacción granulomatosa de presentación exclusivamente cutánea, como efecto adverso medicamentoso tardío secundario al tratamiento con ipilimumab. Así mismo resaltamos la necesidad de realizar en los pacientes tratados con ipilimumab un seguimiento prolongado.

Palabras clave:
Anti-CTLA 4
Inmunoterapia
Melanoma metastásico
Sarcoidosis
Reacción granulomatosa
Evento adverso relacionado inmune-mediado
Reacción adversa medicamentosa

Article

These are the options to access the full texts of the publication Actas Dermo-Sifiliográficas (English Edition)
Member
If you are a member of the AEDV:
Go to the members area of the website of the AEDV, (https://aedv.es/backend/login) and login.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Dermo-Sifiliográficas (English Edition)

Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
902 88 87 40
Calls from outside Spain
+34 932 418 800
Email
Idiomas
Actas Dermo-Sifiliográficas (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.